Not Completed | Completed | Unadjusted | Adjusted | |||||||
---|---|---|---|---|---|---|---|---|---|---|
n | percent | n | percent | RR | 95% CI | p-value | RR | 95% CI | p-value | |
Type of Therapya,b | ||||||||||
Isoniziad + Rifpaentine | 13 | 14.9 | 74 | 85.1 | Reference | Reference | ||||
Rifampin only | 12 | 14.6 | 70 | 85.4 | 1.00 | 0.88, 1.14 | 0.96 | 0.88 | 0.55, 1.38 | 0.57 |
Isoniazid only | 107 | 48.2 | 115 | 51.8 | 0.61 | 0.52, 0.71 | <0.001 | 0.58 | 0.36, 0.93 | 0.02 |
Isoniazid only (vs rifampin only) | 0.61 | 0.52, 0.71 | <0.001 | 0.66 | 0.56, 0.79 | <0.001 | ||||
Clinicb,c | ||||||||||
Public Health | 59 | 22.5 | 203 | 77.5 | Reference | Reference | ||||
Employee Health | 20 | 74.1 | 7 | 25.9 | 0.33 | 0.18, 0.64 | <0.001 | 0.37 | 0.20, 0.69 | <0.01 |
International | 37 | 54.4 | 31 | 45.6 | 0.59 | 0.45, 0.77 | <0.001 | 0.64 | 0.47, 0.85 | <0.01 |
Homeless | 9 | 52.9 | 8 | 47.1 | 0.61 | 0.37, 1.01 | 0.06 | 0.65 | 0.38, 1.09 | 0.10 |
Infectious Diseases | 7 | 41.2 | 10 | 58.8 | 0.76 | 0.51, 1.14 | 0.18 | 0.74 | 0.48, 1.12 | 0.16 |
Type of monitoringa,c | ||||||||||
Weekly DOT/phone calls | 13 | 15.1 | 73 | 84.9 | Reference | Reference | ||||
Monthly clinic visits | 38 | 27.3 | 101 | 72.7 | 0.86 | 0.75, 0.98 | 0.03 | 1.12 | 0.71, 1.76 | 0.62 |
Less often | 81 | 48.8 | 85 | 51.2 | 0.60 | 0.51, 0.72 | <0.001 | 1.21 | 0.75, 1.96 | 0.43 |
Side effectsc | 37 | 28.2 | 94 | 71.8 | 1.13 | 0.98, 1.30 | 0.09 | 1.03 | 0.90, 1.18 | 0.66 |
Number of other medical problemsa,d | ||||||||||
0 | 47 | 26.6 | 130 | 73.5 | Reference | Reference | ||||
1-2 | 42 | 35.3 | 77 | 64.7 | 0.88 | 0.75, 1.03 | 0.12 | 1.00 | 0.84, 1.19 | 1.00 |
3+ | 43 | 45.3 | 52 | 54.7 | 0.75 | 0.61, 0.91 | 0.01 | 1.08 | 0.88, 1.33 | 0.47 |